BIOS Podcast – Future of Drug Delivery w/ Samir Mitragotri – Professor at Harvard, Core Faculty member at the Wyss InstitutePrevious Next
Samir Mitragotri is the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering. Samir is an elected member of the National Academies of Engineering and Medicine, and elected fellow of the American Institute of Medical and Biological Engineering, the American Association for the Advancement of Science, the National Academy of Inventors, the Controlled Release Society, the Biomedical Engineering Society, and the American Association of Pharmaceutical Scientists. He is a Thomson Reuters Highly Cited Researcher. He serves on the editorial boards of several journals and currently serves as the founding Editor-in-Chief of Bioengineering and Translational Medicine.
Samir has made groundbreaking contributions to the field of biological barriers and drug delivery systems. His research, which is focused on the fundamental understanding of biological barriers, has led to the development of new materials and technologies for diagnosis and treatment of various ailments including diabetes, cancer, cardiovascular diseases, skin conditions and infections. Many of his technologies have advanced to human clinical studies and products. Samir’s key technical contributions include the development of novel transdermal and oral delivery systems. Specifically in transdermal drug delivery, Samir has established a fundamental knowledgebase of transport properties of skin and has pioneered numerous technologies including low-frequency ultrasound, pulsed microjet injector, high throughput screening (INSIGHT), in situ hydrogels and ionic liquids for transdermal drug delivery. He has also developed ionic liquid-based technologies for oral delivery of insulin, monoclonal antibodies and other biologics. Samir has also developed unique bio-inspired nanoparticles that hitchhike on circulatory cells to avoid immune clearance and allow targeted delivery to tissues.
Samir is the author of more than 400 publications in the area of drug delivery and biomaterials, has given close to 500 invited and contributed presentations worldwide, and is an inventor on more than 200 pending or issued patents. He is a co-founder of several companies that are developing therapeutic or diagnostic products based on his inventions.
BIOS unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.